Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Chimeric Therapeutics Ltd C.CHM


Primary Symbol: CHMMF

Chimeric Therapeutics Limited is an Australia-based clinical-stage cell therapy company. The Company is focused on the discovery, development, and commercialization of cell therapies for patients with cancer. Its pipeline includes CHM 1101 and CHM 2101. Its CHM 1101 (CLTX CAR-T) is a CAR-T therapy developed for the treatment of patients with solid tumors. CHM-1101 is being studied in a Phase 1B clinical trial in recurrent/ progressive glioblastoma. CHM 2101 is a third generation CDH17 CAR T, which is in preclinical development with a planned Phase I clinical trial in neuroendocrine tumors, colorectal, pancreatic and gastric cancer. Its pipeline also includes the CORE-NK platform, a clinically validated, off-the-shelf natural killer (NK) cell therapy platform to their portfolio (CHM 0201). The Company is also focused on the development of NK and CAR NK assets with plans for Phase 1B clinical trials in solid tumors and blood cancers.


OTCPK:CHMMF - Post by User

Comment by monstapeakeon Jan 24, 2021 5:04pm
117 Views
Post# 32371767

RE:TOXIC RINSE

RE:TOXIC RINSEthis dude makes a point about the major component of flex 10.  Following is from the immunoflex.com website:

n-acetyl-l-cysteine (NAC)

  • NAC is a precursor to glutathione, a molecule that helps to protect cells against oxidative damage. 

  • Glutathione deficiency is implicated in a wide variety of diseases

  • Although NAC is classified as a natural health product, it is also widely used in hospitals around the world.

  • Most commercially available NAC is unprotected  from oxidation and rapidly oxidizes to Di-NAC, a powerful pro-inflammatory subverting the anti-inflammatory activity of the NAC.

It seems, and I am no scientist, that this compound is incorporated with Cannabinoids for the Flex 10 product recently approved by Canadian Health authorities. The combination of the cannabis and NAC may make a drug consistent with helping the immune system, but NAC has been around along time.  It is not that this contentious poster is without merit, it is just that he makes a poor presentation of his vision that come off offensive.  I am long this stock and looking into it more have to question the veracity of the claims being made.  Most of management described on the company site seem like they could fit the role of used car salesmen.  The immunoflex.com site does list some credible scientist behind this venture with pharma experience and phds but  have to be skeptical when a stock making a milestone achievement does not go on to new highs. Maybe that is around the corner, but this company also has weed investments that could be beneficial to investors.  Just voicing my concerns and hoping for the best,  glta,  mpke
<< Previous
Bullboard Posts
Next >>